Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ARRY

ARRY - Array BioPharma Inc Stock Price, Fair Value and News

12.82USD+0.42 (+3.39%)Market Closed

Market Summary

ARRY
USD12.82+0.42
Market Closed
3.39%

ARRY Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)

ARRY Stock Price

View Fullscreen

ARRY RSI Chart

ARRY Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

17.45

Price/Sales (Trailing)

1.44

EV/EBITDA

10.29

Price/Free Cashflow

8.92

ARRY Price/Sales (Trailing)

ARRY Profitability

Operating Margin

27.71%

EBT Margin

10.62%

Return on Equity

48.23%

Return on Assets

6.84%

Free Cashflow Yield

11.21%

ARRY Fundamentals

ARRY Revenue

Revenue (TTM)

1.4B

Rev. Growth (Yr)

-59.29%

Rev. Growth (Qtr)

-55.09%

ARRY Earnings

Earnings (TTM)

111.5M

Earnings Growth (Yr)

-92.69%

Earnings Growth (Qtr)

-89.85%

Breaking Down ARRY Revenue

Last 7 days

-2.4%

Last 30 days

17.0%

Last 90 days

-3.7%

Trailing 12 Months

-39.6%

How does ARRY drawdown profile look like?

ARRY Financial Health

Current Ratio

2.73

Debt/Equity

2.84

Debt/Cashflow

0.36

ARRY Investor Care

Shares Dilution (1Y)

0.61%

Diluted EPS (TTM)

0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.4B000
20231.7B1.8B1.6B1.6B
2022905.7M1.1B1.5B1.6B
2021683.2M764.8M814.0M853.3M
2020704.1M760.3M816.5M872.7M
201900469.3M647.9M
2018000290.8M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Array BioPharma Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 07, 2024
hottinger tyson
sold (taxes)
-87,682
13.44
-6,524
chief legal officer
May 14, 2024
rose travis
sold (taxes)
-36,017
12.62
-2,854
chief revenue officer
Apr 18, 2024
hostetler kevin g.
sold (taxes)
-164,331
10.97
-14,980
chief executive officer
Mar 22, 2024
hottinger tyson
sold (taxes)
-49,436
12.65
-3,908
chief legal officer
Mar 20, 2024
hostetler kevin g.
sold
-100,565
12.3
-8,176
chief executive officer
Mar 19, 2024
manning neil
sold (taxes)
-15,378
11.73
-1,311
chief operations officer
Mar 19, 2024
rose travis
sold (taxes)
-13,947
11.73
-1,189
chief revenue officer
Mar 19, 2024
hottinger tyson
sold (taxes)
-27,729
11.73
-2,364
chief legal officer
Mar 19, 2024
collins terrance l
sold (taxes)
-20,891
11.73
-1,781
chief human resources officer

1–10 of 50

Which funds bought or sold ARRY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
3,196
3,196
-%
Jun 11, 2024
American Trust
reduced
-7.11
-61,843
290,268
0.02%
Jun 06, 2024
WESTWOOD HOLDINGS GROUP INC
sold off
-100
-3,970,000
-
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
269
1,473,000
2,124,000
-%
May 28, 2024
Boston Partners
sold off
-100
-20,851,900
-
-%
May 24, 2024
Cetera Investment Advisers
added
35.34
49,503
295,606
-%
May 23, 2024
Redwood Grove Capital, LLC
added
25.67
1,736,860
16,794,300
5.23%
May 20, 2024
Virtu Financial LLC
sold off
-100
-250,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-34.47
-1,735,050
2,411,680
-%
May 16, 2024
B. Riley Wealth Advisors, Inc.
new
-
616,194
616,194
0.02%

1–10 of 30

Are Funds Buying or Selling ARRY?

Are funds buying ARRY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARRY
No. of Funds

Unveiling Array BioPharma Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
electron capital partners, llc
5.4%
8,198,076
SC 13G
Feb 13, 2024
hill city capital, lp
5.85%
8,840,335
SC 13G/A
Feb 13, 2024
vanguard group inc
9.18%
13,886,457
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 24, 2024
blackrock inc.
11.6%
17,529,949
SC 13G/A
Nov 17, 2023
hill city capital, lp
5.14%
7,770,335
SC 13G
Feb 09, 2023
vanguard group inc
9.20%
13,841,925
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 08, 2023
invesco ltd.
3.5%
5,243,222
SC 13G/A
Jan 30, 2023
blackrock inc.
10.7%
16,134,994
SC 13G/A

Recent SEC filings of Array BioPharma Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
8-K
Current Report
May 31, 2024
SD
SD
May 28, 2024
8-K
Current Report
May 16, 2024
4
Insider Trading
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
Apr 22, 2024
4
Insider Trading
Apr 10, 2024
DEFA14A
DEFA14A
Apr 10, 2024
ARS
ARS

Peers (Alternatives to Array BioPharma Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
76.7B
68.9M
-13.58% -46.88%
-5.0K
1.1K
51.94% 28.11%
28.1B
3.6B
32.79% 38.83%
27.4
7.88
27.28% 2360.58%
16.2B
1.8B
4.10% -34.54%
58.68
8.86
-30.11% -43.96%
MID-CAP
2.8B
2.1B
6.39% -34.59%
-1.93
1.32
-11.90% -7091.51%
2.1B
2.2B
-23.42% -86.60%
-8.13
0.95
-34.19% -231.31%
1.9B
1.4B
16.97% -39.56%
17.45
1.44
-21.04% 85.86%
SMALL-CAP
1.2B
474.7M
7.33% -72.19%
38.47
2.47
30.38% -78.20%
491.0M
1.8B
-0.70% -74.27%
-3.38
0.22
14.74% -307.59%
59.2M
98.7M
-6.00% -81.78%
-1.25
0.6
-13.73% 43.41%
2.8M
458.3K
-25.00% -25.00%
-0.2
6.04
-62.52% 37.22%
1.7M
154.9M
- -97.50%
-0.02
0.01
10.63% -80.26%

Array BioPharma Inc News

Latest updates
Yahoo Finance4 months ago
Investopedia4 years ago

Array BioPharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Revenue-55.1%153342350508377402515420301220189197248181139115438318198-
Cost Of Revenue-62.1%98.0025926335827932943838027422418317620214511393.00319-151-
Gross Profit-33.2%55.0082.0087.0015098.0073.0077.0040.0027.00-4.276.0021.0046.0035.0027.0022.00118-47.00-
Operating Expenses-10.6%47.0052.0047.0054.0050.0057.0059.0053.0065.0016.0025.0021.0031.0038.0032.0021.0017.00-19.00-
  S&GA Expenses-13.6%38.0044.0037.0040.0038.0038.0039.0029.0045.0023.0018.0015.0025.0021.0012.0011.0012.00-10.00-
EBITDA Margin0.0%0.17*0.17*0.16*0.16*0.11*0.07*0.04*-0.04*-0.05*-0.02*0.02*0.04*0.05*-------
Interest Expenses-6.8%9.0010.0013.0010.0011.0013.009.008.007.007.0013.007.009.007.001.002.005.00-4.00-
Income Taxes8.5%1.001.007.0022.008.0014.0010.00-18.44-14.74-5.24-5.36-1.802.001.001.00-5.8023.00-6.00-
Earnings Before Taxes-84.6%3.0023.0030.0087.0038.009.0051.00-23.46-40.68-27.13-32.92-7.356.00-9.20-5.81-3.4496.00-24.00-
EBT Margin-6.1%0.11*0.11*0.10*0.10*0.04*0.00*-0.03*-0.11*-0.12*-0.07*-0.05*-0.02*-0.02*-------
Net Income-89.9%2.0021.0023.0065.0030.00-5.2541.00-5.02-25.94-21.90-27.56-5.525.00-9.77-7.232.0074.00-18.00-
Net Income Margin-6.5%0.08*0.09*0.07*0.07*0.03*0.00*-0.01*-0.07*-0.09*-0.06*-0.05*-0.02*-0.01*-------
Free Cashflow-49.1%45.0089.0069.0015.0042.0094.00102-12.20-52.45-98.45-32.78-92.59-42.72-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Assets-4.5%1,6291,7071,7791,8531,7791,7061,7341,8191,7841,143770617586656552676800924510
  Current Assets-7.0%774832863908867831871902816852485325288375265--620174
    Cash Equivalents15.5%28824917415614813463.0051.0049.0036811618.0019.0010827.0038.0010336141.00
  Inventory10.3%17916221620725523327033029920617313812511897.00--14855.00
  Net PPE-4.3%27.0028.0030.0031.0026.0023.0020.0018.0017.0011.0010.0010.0010.0010.0010.00--11.0011.00
  Goodwill-2.3%4254364274412.0041640141844234370.0070.0070.0070.0070.00--70.0070.00
Liabilities-5.7%1,0331,0961,1621,2401,2751,2821,3351,4141,332975534689654737175323471618245
  Current Liabilities-15.5%284336401435471465513513433245214168233289147--591135
  Long Term Debt-0.5%658661659702706720725794778711299494392424----59.00
    LT Debt, Current4.8%22.0021.0039.0037.0034.0039.0048.0051.0048.004.004.004.004.004.00---56.0020.00
    LT Debt, Non Current-0.5%658661659702706720725794778711299494392424----59.00
Shareholder's Equity-10.8%231259278287158124111110170-1.00------305-
  Retained Earnings1.7%-128-130-153-176-241-267-262-302-297-271-250-222-216-221-----
  Additional Paid-In Capital-3.2%334345408418426383393402411203251150148140-----
Shares Outstanding0.3%151151151151151150150149148130128127127------
Float----2,898---1,552---1,981-------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Cashflow From Operations-49.5%47,50293,98171,61820,54045,81697,470104,787-10,667-50,097-97,350-31,728-91,961-42,148104,29521,400-47,324-200,576---
  Share Based Compensation38.0%3,9262,8453,3844,9453,3663,3054,2052,9644,5082,0512,2391,5567,9111,5458536531,758---
Cashflow From Investing54.2%-2,386-5,206-2,191-5,541-3,883-3,931-2,793-1,540-376,173-1,105-1,052-2,605-10,570-728-345-97.00-168---
Cashflow From Financing73.6%-4,575-17,319-45,128-15,552-23,762-24,706-89,55121,961100,736349,734131,48993,115-36,590-22,270-31,895-17,416-57,692---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ARRY Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 153,403$ 376,773
Cost of revenue  
Cost of product and service revenue94,674275,594
Amortization of developed technology3,6393,639
Total cost of revenue98,313279,233
Gross profit55,09097,540
Operating expenses  
General and administrative37,78438,142
Change in fair value of contingent consideration(735)1,338
Depreciation and amortization9,62710,602
Total operating expenses46,67650,082
Income from operations8,41447,458
Other expense, net  
Other income, net814194
Interest income3,6801,231
Foreign currency loss(499)(194)
Interest expense(8,940)(10,731)
Total other expense, net(4,945)(9,500)
Income before income tax expense3,46937,958
Income tax expense1,3048,323
Net income2,16529,635
Preferred dividends and accretion13,50212,484
Net (loss) income to common shareholders, basic(11,337)17,151
Net (loss) income to common shareholders, diluted$ (11,337)$ 17,151
(Loss) income per common share  
Basic (in dollars per share)$ (0.07)$ 0.11
Diluted (in dollars per share)$ (0.07)$ 0.11
Weighted average number of common shares outstanding  
Basic (in shares)151,351150,607
Diluted (in shares)151,351151,795

ARRY Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 287,620$ 249,080
Accounts receivable, net of allowance of $4,614 and $3,824, respectively229,224332,152
Inventories178,695161,964
Prepaid expenses and other78,88489,085
Total current assets774,423832,281
Property, plant and equipment, net26,68927,893
Goodwill425,414435,591
Other intangible assets, net339,177354,389
Deferred income tax assets13,85415,870
Other assets49,72640,717
Total assets1,629,2831,706,741
Current liabilities  
Accounts payable93,404119,498
Accrued expenses and other34,44970,211
Accrued warranty reserve2,2792,790
Income tax payable7,0305,754
Deferred revenue86,55866,488
Current portion of contingent consideration1,8881,427
Current portion of debt22,49621,472
Other current liabilities35,55848,051
Total current liabilities283,662335,691
Deferred income tax liabilities62,88066,858
Contingent consideration, net of current portion6,3138,936
Other long-term liabilities19,26020,428
Long-term warranty3,4743,372
Long-term debt, net of current portion657,708660,948
Total liabilities1,033,2971,096,233
Commitments and contingencies (Note 11)
Series A Redeemable Perpetual Preferred Stock of $0.001 par value; 500,000 authorized; 439,596 and 432,759 shares issued as of March 31, 2024 and December 31, 2023, respectively; liquidation preference of $493.1 million at both dates364,762351,260
Stockholders’ equity  
Preferred stock of $0.001 par value - 4,500,000 shares authorized; none issued at respective dates00
Common stock of $0.001 par value - 1,000,000,000 shares authorized; 151,726,568 and 151,242,120 shares issued at respective dates151151
Additional paid-in capital333,570344,517
Accumulated deficit(128,065)(130,230)
Accumulated other comprehensive income25,56844,810
Total stockholders’ equity231,224259,248
Total liabilities, redeemable perpetual preferred stock and stockholders’ equity$ 1,629,283$ 1,706,741
ARRY
Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.
 CEO
 WEBSITEhttps://arraytechinc.com
 INDUSTRYSolar
 EMPLOYEES1096

Array BioPharma Inc Frequently Asked Questions


What is the ticker symbol for Array BioPharma Inc? What does ARRY stand for in stocks?

ARRY is the stock ticker symbol of Array BioPharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Array BioPharma Inc (ARRY)?

As of Tue Jun 18 2024, market cap of Array BioPharma Inc is 1.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARRY stock?

You can check ARRY's fair value in chart for subscribers.

What is the fair value of ARRY stock?

You can check ARRY's fair value in chart for subscribers. The fair value of Array BioPharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Array BioPharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARRY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Array BioPharma Inc a good stock to buy?

The fair value guage provides a quick view whether ARRY is over valued or under valued. Whether Array BioPharma Inc is cheap or expensive depends on the assumptions which impact Array BioPharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARRY.

What is Array BioPharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, ARRY's PE ratio (Price to Earnings) is 17.45 and Price to Sales (PS) ratio is 1.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARRY PE ratio will change depending on the future growth rate expectations of investors.